Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Uijeongbu-si
Clinical trial register · South Korea

Clinical Trials in Uijeongbu-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3409 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:18 UTC
3409
Studies in scope
all four open statuses
1874
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Seoul 2866 Daegu 553 Seongnam-si 485 Busan 470 Goyang-si 399

Trials with a site in Uijeongbu-si

29 of 3409 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Bucheon-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2026-10-26
Not yet open
Seoul National University Hospital
Not applicable
3,000
Seongnam-si, Uijeongbu-si, Daegu, Seoul
2026-08-24
Not yet open
High-Flow Nasal Cannula After Major Abdominal Surgery to Prevent Postoperative Pulmonary Complications
NCT07528404Postoperative Complications, Atelectasis, Pneumonia, Respiratory Insufficiency
Uijeongbu St. Mary Hospital
Not applicable
580
Uijeongbu-si
2026-07-01
Not yet open
Naltrexone for Nonsuicidal Self-Injury
NCT07641283Nonsuicidal Self-Injury, Self-Injurious Behavior
Seoul National University Hospital
Not applicable
150
Uijeongbu-si, Seoul
2026-06
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Wŏnju, Anyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Daegu, Daejeon
2026-05-11
Active, closed
EverEx Inc.
Not applicable
156
Guri-si, Gwangmyeong, Uijeongbu-si, Seoul
2026-03-19
Recruiting
Eli Lilly and Company
Phase 3
900
Daegu, Dongjak-gu, Seoul, Uijeongbu-si
2026-02-09
By invitation
Novo Nordisk A/S
Observational
500
Goyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2025-11-10
Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
NCT06902545Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Korea, Inc.
Observational
377
Goyang-si, Suwon, Uijeongbu-si, Yangsan, Hwasun Gun, Daejeon, Seoul
2025-04-03
Recruiting
AstraZeneca
Phase 3
990
Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wŏnju
2025-03-18
Recruiting
Dianthus Therapeutics
Phase 3
256
Daegu, Daejeon, Seoul, Uijeongbu-si, Yangsan
2025-02-10
Recruiting
Endovision Co., Ltd.
Not applicable
286
Uijeongbu-si
2025-02-04
Recruiting
IRIS-Coroflex NEO Cohort
NCT06177743Coronary Artery Stenosis, Coronary Artery Disease
Seung-Jung Park
Observational
1,000
Seoul, Bucheon-si, Daegu, Gwangju, Ilsan, Sejong, Suwon, Uijeongbu-si
2025-01-09
Recruiting
Seoul St. Mary's Hospital
Not applicable
800
Incheon, Seoul, Suwon, Uijeongbu-si
2024-11-19
Recruiting
Boryung Pharmaceutical Co., Ltd
Observational
1,052
Seoul, Uijeongbu-si
2024-07-15
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
330
Uijeongbu-si, Anyang-si, Busan, Daegu
2024-03-26
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Busan, Daegu, Donggu, Goyang, Seoul, Uijeongbu-si, Ulsan
2024-03-13
Recruiting
AstraZeneca
Phase 3
5,250
Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan
2024-02-21
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Ascentage Pharma Group Inc.
Phase 3
333
Busan, Gyeonggi-do, Seoul, Uijeongbu-si
2024-02-05
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.
Phase 3
350
Busan, Seoul, Uijeongbu-si
2023-08-31
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Dongan-Gu, Anyang-Si, Guri-si, Uijeongbu-si, Jongno-gu, Seodaemun-gu, Seongbuk-Gu, Cheonan, Daejeon
2023-07-06
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Uijeongbu-si, Busan, Jeollanam, Seoul
2022-08-30
Active, closed
Yuhan Corporation
Observational
2,001
Chilgok, Chuncheon, Wŏnju, Bucheon-si, Uijeongbu-si, Iksan, Seoul, Busan
2022-06-24
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Uijeongbu-si, Seoul
2021-10-06
Recruiting
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT04499859Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
Kiyuk Chang, MD,PhD
Phase 4
3,548
Bucheon-si, Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-10-01
Recruiting
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
NCT03459534Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory, CML - Philadelphia Chromosome
Il-Yang Pharm. Co., Ltd.
Phase 3
173
Uijeongbu-si
2018-06-25
Active, closed
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
NCT02112214Gastric Cancer, Helicobacter Pylori Infection
National Cancer Center, Korea
Phase 3
5,224
Busan, Chuncheon, Daegu, Goyang, Gwangju, Incheon, Seoul, Uijeongbu-si
2014-06
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-south-korea/city/uijeongbu-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,409 studies in total at the last sync on 17 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in Uijeongbu-si.

How many clinical trials are recruiting in Uijeongbu-si?

17 of the 29 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Uijeongbu-si), 29 studies
PhaseStudiesRecruitingShare
Phase 313844.8%
Not applicable7224.1%
Observational6420.7%
Phase 4226.9%
Phase 1/2113.4%

Most active sponsors

Lead sponsors with the most studies (Uijeongbu-si)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals52
Novo Nordisk A/S31
Ascentage Pharma Group Inc.22
AstraZeneca22
Seoul National University Hospital20
Astellas Pharma Korea, Inc.11
Boryung Pharmaceutical Co., Ltd11
Dianthus Therapeutics11
Eli Lilly and Company11
Endovision Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.